Magenta Therapeutics has thrust Dianthus Therapeutics onto Wall Street through a reverse merger months after proceeding with wind-down plans.
Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus’ portfolio of next-generation antibody complement therapeutics Combined company is expected to have...
Magenta Therapeutics will give its spot on Nasdaq to privately-held Dianthus Therapeutics after a patient death spurred an end to Magenta’s clinical work and an exit for most of the company’s employees.
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
After a patient death, Magenta Therapeutics scrapped its stem cell transplant drug and went searching for alternatives last week. As it seeks an exit, the biotech has now laid off 56 people.
Magenta Therapeutics to Explore Strategic Alternatives
A week after pausing a leukemia trial due to the death of a patient, Magenta Therapeutics is halting development of all its programs and exploring a potential sale or other measures to wind down operations.
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117. The known information has been reported to the U.S. Food and Drug Administration (FDA) as a Suspected Unexpected Serious Adverse Reaction (SUSAR). After consultation with the trial’s safety Cohort Review Committee and with the highest regard for patient safety, Magenta has voluntarily paused dosing in the clinical trial and is working to evaluate the totality of available data and determine next steps for the development of MGTA-117.
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
Magenta Therapeutics has stopped dosing a group of patients after a serious adverse event was reported in a phase 1/2 trial for the biotech’s leukemia med.